Cipla USA, Inc.

Complete recall history across all FDA and CPSC categories — 15 total recalls

Cipla USA, Inc. appears in recall records across 1 category. This page consolidates all FDA food, drug, and medical device enforcement actions, plus CPSC consumer product recalls associated with this company. Recall data is sourced from openFDA and CPSC public databases.

Drug Recalls (15)

FDA drug safety enforcement actions by Cipla USA, Inc.

Date Product Reason Class
Mar 16, 2026 Cinacalcet Hydrochloride Tablets, 60 mg, 30 Tablets per bottle, Rx Only, Manu... CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily int... Class II
Mar 16, 2026 Cinacalcet Hydrochloride Tablets, 90 mg, 30 Tablets per bottle, Rx Only, Manu... CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily int... Class II
Mar 16, 2026 Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manu... CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily int... Class II
Mar 13, 2026 Lanreotide Injection, 120 mg*/0.5 mL, Box contains 1 Pre-filled syringe and 1... Lack of Assurance of Sterility: Due to an FDA observation at the contract man... Class II
Mar 13, 2026 Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Singl... Lack of Assurance of Sterility: Due to an FDA observation at the contract man... Class II
Feb 18, 2026 Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufac... Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-t... Class III
Feb 18, 2026 Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufac... Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-t... Class III
Jan 2, 2026 Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep ... Presence of Particulate Matter. Class II
Dec 22, 2025 Diclofenac Sodium Topical Gel, 1%, NET WT 100 g (3.53 oz), Manufactured by: D... Failed PH Specifications Class III
Nov 14, 2025 Cinacalcet Hydrochloride Tablets, 60 mg, 30 Tablets per bottle, Rx Only, Manu... CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet... Class II
Nov 14, 2025 Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manu... CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet... Class II
Nov 14, 2025 Cinacalcet Hydrochloride Tablets, 90 mg, 30 Tablets per bottle, Rx Only, Manu... CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet... Class II
Oct 24, 2025 Lanthanum Carbonate chewable tablets, 1000mg*, 10x9 bottles per patient pack ... Failed stability specifications: Out of specification for hardness test Class II
Oct 24, 2025 Lanthanum Carbonate chewable tablets, 1000mg*, 10x9 bottles per patient pack ... Failed stability specifications: Out of specification for hardness test Class II
Jul 24, 2025 Albuterol Sulfate, Inhalation Aerosol, 90 mcg, 200 metered Inhalations, NET C... Failed Stability Specifications: Out of specification results was observed in... Class III
Jun 30, 2025 Budesonide Inhalation Suspension, 0.5mg/2ml, 30 single-dose ampules per carto... Lack of Assurance of Sterility: A market complaint was received for leakage a... Class II
Oct 23, 2024 Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manuf... Failed Tablet/Capsule Specifications: Complaints received of crushed and brok... Class II
Oct 23, 2024 Lanthanum Carbonate Chewable Tablets, 1000mg, 10-count bottle, Rx only, Manuf... Failed Tablet/Capsule Specifications: Complaints received of crushed and brok... Class II
Mar 26, 2024 Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USP, 0.5 mg & 3... Short fill: Complaints received of less fill volume in respule and few drops ... Class II
Jun 27, 2023 Albuterol Sulfate Inhalation Aerosol, 90 mcg, 200 Metered Inhalation, net con... Defective container: empty inhaler and leakage observed through the inhaler v... Class I

Frequently Asked Questions

A high number of recalls does not necessarily indicate that a company is unsafe. Large manufacturers that produce thousands of products across multiple categories will statistically appear in recall databases more frequently. What matters more is the severity of each recall (Class I being the most serious), the speed of response, and whether the company proactively identified and addressed the issue. Companies with robust safety programs often catch problems earlier.

Food, drug, and medical device recall data comes from the FDA's openFDA enforcement database, which contains all FDA enforcement reports. Consumer product recall data comes from the U.S. Consumer Product Safety Commission (CPSC). Both sources are public government databases that are updated regularly. RecallCheck aggregates these sources to provide a unified view of a company's recall history.

The FDA classifies recalls into three categories. Class I is the most serious — there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. Class II means the product may cause temporary or medically reversible health problems, or the probability of serious consequences is remote. Class III is the least serious — the product is unlikely to cause adverse health consequences. CPSC product recalls do not use this classification system.

Yes. You can search for any company using the firm/manufacturer pages for each category: Food Firms, Drug Firms, Device Firms, or Product Manufacturers. You can also use the search functionality on any browse page to find recalls by company name.

Explore More Recalls

Search recalls by category, state, reason, or firm across all our databases.